Stroke

Cardiovascular 3 original drugs

Novel Drugs

Reformulations

Drug Targets

Cardiovascular indication. Stroke has 3 FDA-approved novel treatments, led by SHINE, with 374 active industry clinical trials across 17 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Stroke Market Leaders

Companies with the most FDA-approved novel Stroke drugs.

Phase 3 Readouts Pro

12 active Phase 3 trials with confidence-graded completion dates.

Full calendar →

Q3 2026

Drug: Normal Saline

Pharmazz, Inc.

Estimated · fresh NCT05691244

Q4 2026

Milvexian

Johnson & Johnson

Estimated · fresh NCT05702034

Q4 2026

Neuroncell-EX

Cytopeutics Sdn. Bhd.

Estimated · fresh NCT06129175

Unlock 9 more readouts with confidence-graded estimates

Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Stroke Treatments by Mechanism

Top 6 mechanisms across 10 industry trials with a known mechanism of action.

See full pipeline →

Fibrin/Plasminogen/tPA

2 trials 1 active 1 sponsor

PCSK9 Inhibitor

1 trials 1 active 1 sponsor

Plasminogen

2 trials 2 sponsors

Acetylcholine Release Inhibitor

2 trials 1 sponsor

Integrin Receptor Antagonist

2 trials 1 sponsor

Leukocyte Growth Factor

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Stroke Clinical Pipeline by Phase

205 industry-sponsored trials across 137 sponsors

View full landscape →

Showing 17 of 17 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Pharmasoft	Mexidol	—	RECRUITING	2027-04	NCT07575984
Dr. Willmar Schwabe GmbH & Co. KG	Extract of Ginkgo Biloba Leaves Tablets 240 mg (2 x 40 mg, t.i.d.)	—	RECRUITING	2027-12-31	NCT07220538
Route 92 Medical, Inc.	—	—	RECRUITING	2029-05-31	NCT07436156
Amgen	Evolocumab	PCSK9 Inhibitor [EPC]	ACTIVE NOT RECRUITING	2027-05-29	NCT05284747
SK Chemicals Co., Ltd.	Renexin CR 200/160mg	—	COMPLETED	2025-10-02	NCT05445895
Pharmasoft	Mexidol	—	COMPLETED	2023-09-12	NCT06221826
Penumbra Inc.	intravenous (IV) recombinant human tissue plasminogen activator (rtPA)	—	COMPLETED	2016-10	NCT01429350
Ipsen	Botulinum toxin type A	—	COMPLETED	2016-03	NCT02321436
Avanir Pharmaceuticals	Nuedexta (DM 20 mg/Q 10 mg)	—	COMPLETED	2015-05	NCT01799941
Jiangsu Kanion Pharmaceutical Co., Ltd	Ginkgolides Meglumine Injection	—	COMPLETED	2014-10	NCT01958957
Jiangsu Kanion Pharmaceutical Co., Ltd	Ginkgolides Meglumine Injection	—	COMPLETED	2014-06	NCT02046031
Kinetic Muscles	—	—	COMPLETED	2013-09	NCT01144715
Medtronic Cardiac Rhythm and Heart Failure	—	—	COMPLETED	2013-05	NCT00924638
Sanofi	Clopidogrel	—	COMPLETED	2012-05	NCT00814268
Tibion Bionics, Inc.	—	—	COMPLETED	2011-12	NCT01499862
Stryker Neurovascular	—	—	COMPLETED	2011-08	NCT01088672
Biotronik, Inc.	Home Monitoring Guided OAC	—	TERMINATED	2013-06	NCT00559988

Showing 62 of 62 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Pharmazz, Inc.	Drug: Normal Saline	—	RECRUITING	2026-09	NCT05691244
Cytopeutics Sdn. Bhd.	Neuroncell-EX	—	RECRUITING	2026-11-30	NCT06129175
DiaMedica Therapeutics Inc	Recombinant human tissue kallikrein	—	RECRUITING	2026-12	NCT05065216
Shin Poong Pharmaceutical Co. Ltd.	SP-8203	—	RECRUITING	2027-03-30	NCT06660719
Shanghai Hutchison Pharmaceuticals Limited	SHPL-49 Injection	—	RECRUITING	2027-06-30	NCT07241520
CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.	rhTNK-tPA	—	RECRUITING	2027-09-30	NCT07201688
Boehringer Ingelheim	Tenecteplase	Fibrin/Plasminogen/tPA	RECRUITING	2027-10-02	NCT07361302
Supergene, LLC	non-immunogenic staphylokinase	—	RECRUITING	2028-11-01	NCT07324837
Corxel Pharmaceuticals	JX10	—	RECRUITING	2029-10-31	NCT06990867
Tatchempharmpreparaty, JSC	Dimephosphon®	—	RECRUITING	2026-01-31	NCT07167550
Johnson & Johnson	Milvexian	—	ACTIVE NOT RECRUITING	2026-11-11	NCT05702034
Moleac Pte Ltd.	MLC1501	—	NOT YET RECRUITING	2028-09	NCT05046106
Bayer	Asundexian (BAY2433334)	—	COMPLETED	2025-10-23	NCT05686070
POLYSAN Scientific & Technological Pharmaceutical Company	Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid)	—	COMPLETED	2024-06-26	NCT05935787
Shanghai Auzone Biological Technology Co., Ltd.	TTYP01 tablets	—	COMPLETED	2024-06-17	NCT06648304
Acticor Biotech	Intravenous glenzocimab (ACT017) 1000 mg	—	COMPLETED	2024-04-30	NCT05070260
Tasly Biopharmaceuticals Co., Ltd.	rhPro-UK	—	COMPLETED	2024-03-14	NCT05700591
Boehringer Ingelheim	tenecteplase	Fibrin/Plasminogen/tPA	COMPLETED	2023-10-08	NCT04915729
Qilu Pharmaceutical Co., Ltd.	Monosialoganglioside	—	COMPLETED	2023-08-30	NCT06742216
Pharmasoft	Mexidol (Ethylmethylhydroxypyridine Succinate)	—	COMPLETED	2023-08-18	NCT06437626
Angde Biotech Pharmaceutical Co., Ltd.	Injection of recombinant human tissue plasminogen kinase derivatives	—	COMPLETED	2023-06-22	NCT05295173
Materia Medica Holding	MMH-MAP	—	COMPLETED	2020-01-27	NCT03815292
Supergene, LLC	Recombinant staphylokinase	—	COMPLETED	2019-03-23	NCT03151993
AbbVie	Botulinum Toxin Type A	—	COMPLETED	2018-09-03	NCT01603615
Boehringer Ingelheim	optional ASA as comedication	—	COMPLETED	2018-08-14	NCT02239120
Merz Pharmaceuticals GmbH	NT 201	—	COMPLETED	2018-02-23	NCT02270736
Boehringer Ingelheim	alteplase	Plasminogen	COMPLETED	2017-12-11	NCT02930837
AbbVie	botulinum toxin Type A	—	COMPLETED	2017-06-29	NCT01603602
Jiangsu Simcere Pharmaceutical Co., Ltd.	Compound Edaravone Injection	—	COMPLETED	2016-12	NCT02430350
Acorda Therapeutics	dalfampridine-ER 7.5mg	—	COMPLETED	2016-09	NCT02271217
Pharmasoft	Mexidol	—	COMPLETED	2016-05-27	NCT02793687
Lanzhou Institute of Biological Products Co., Ltd	Botulinum Toxin Type A for Injection	—	COMPLETED	2016-02	NCT02280083
Pierre Fabre Medicament	F2695	—	COMPLETED	2015-02	NCT01639014
AstraZeneca	Ticagrelor 90 mg	—	COMPLETED	2014-12	NCT01225562
H. Lundbeck A/S	Desmoteplase	—	COMPLETED	2014-07	NCT00790920
Daewoong Pharmaceutical Co. LTD.	Botulinum toxin type A	—	COMPLETED	2014-05	NCT01945684
Hugel	Botulinum toxin type A(Botulax®)	—	COMPLETED	2014-05	NCT01915459
Dexa Medica Group	DLBS1033	—	COMPLETED	2013-11	NCT01790997
Daiichi Sankyo	warfarin tablets	—	COMPLETED	2013-04	NCT00781391
Boston Scientific Corporation	Warfarin	—	COMPLETED	2013-01	NCT01182441
PhotoThera, Inc	—	—	COMPLETED	2012-09	NCT01120301
GSK	GSK1358820(Botulinum toxin type A)	—	COMPLETED	2011-06	NCT01153815
Merck	Vorapaxar 2.5 mg	—	COMPLETED	2010-10-01	NCT00617123
Relox Medical, LLC	Magnesium Chloride	—	COMPLETED	2010-05	NCT00933868
Catalysis SL	Folrex	—	COMPLETED	2010-03	NCT01016119
Merck	Telcagepant	—	COMPLETED	2009-09-02	NCT00662818
Coherex Medical	—	—	TERMINATED	2023-12-21	NCT03302494
Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC	Phase 2; Low Dose MYOBLOC (10,000 Units)	—	TERMINATED	2023-04-23	NCT04815967
Dexa Medica Group	DLBS1033	—	TERMINATED	2023-02-21	NCT02133521
BrainsGate	—	—	TERMINATED	2018-06	NCT01874093
Bayer	Rivaroxaban (Xarelto, BAY59-7939)	—	TERMINATED	2018-02-15	NCT02313909
Roche	Alteplase	Plasminogen	TERMINATED	2017-03-22	NCT02072226
Dexa Medica Group	DLBS1033	—	TERMINATED	2017-02	NCT02362984
Acorda Therapeutics	dalfampridine-ER 7.5 mg	—	TERMINATED	2017-01	NCT02422940
AbbVie	onabotulinumtoxinA	Acetylcholine Release Inhibitor [EPC]	TERMINATED	2015-12	NCT02145676
Cerevast Therapeutics, Inc.	Standard of care tPA therapy for acute ischemic stroke	—	TERMINATED	2015-04	NCT01098981
H. Lundbeck A/S	Desmoteplase	—	TERMINATED	2014-10	NCT00856661
Codman & Shurtleff	Aspirin and Clopidogrel (Medical therapy)	—	TERMINATED	2013-04	NCT00816166
D-Pharm Ltd.	DP-b99	—	TERMINATED	2012-04	NCT00893867
Merck	Acadesine	—	TERMINATED	2010-10	NCT00872001
ZZ Biotech, LLC	3K3A-APC	—	WITHDRAWN	2026-07	NCT05484154
AbbVie	onabotulinumtoxinA	Acetylcholine Release Inhibitor [EPC]	WITHDRAWN	2017-05	NCT02145689

Showing 84 of 84 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Shanghai QuietD Biotechnology Co., Ltd.	QD202	—	RECRUITING	2026-08	NCT07581210
Fujian Shengdi Pharmaceutical Co., Ltd.	HRS-7450 Injection	—	RECRUITING	2026-10	NCT07233070
Kunming Pharmaceuticals, Inc.	The KPCXM18 injection	—	RECRUITING	2026-10-18	NCT07279493
Changzhou Qianhong Bio-pharma Co., Ltd.	QHRD106 Injection (Low-dose group)	—	RECRUITING	2026-10-31	NCT07396337
NoNO Inc.	NoNO-42	—	RECRUITING	2026-12	NCT06403267
Shanghai Pharmaceuticals Holding Co., Ltd	LT3001 Drug:high dose	—	RECRUITING	2026-12-10	NCT05686642
ThromBio Pty. Ltd.	TBO-309: 60 mg	—	RECRUITING	2026-12-30	NCT06813651
Basking Biosciences, Inc.	BB-031	—	RECRUITING	2027-06	NCT06226805
Translational Sciences, Inc.	TS23	—	RECRUITING	2027-07	NCT05948566
Tasly Pharmaceutical Group Co., Ltd	B2065	—	RECRUITING	2027-12	NCT07371624
Takeda	TAK-755	—	RECRUITING	2027-12-06	NCT07392450
Astellas	ASP2246	—	RECRUITING	2030-02-28	NCT07318714
Shaanxi Micot Pharmaceutical Technology Co., Ltd.	MT200605	—	RECRUITING	2026-05	NCT07205328
Lumosa Therapeutics Co., Ltd.	LT3001 Drug Product	—	RECRUITING	2026-03-31	NCT05198323
Shenzhen Wingor Biotechnology Co., Ltd.	hUC-MSCs treatment (high dose)	—	RECRUITING	2026-03-05	NCT07084012
Philips Portuguesa S.A.	—	—	RECRUITING	2025-08	NCT04903951
NC Medial Research Inc	NCS-01	—	ACTIVE NOT RECRUITING	2027-10	NCT03915431
Shionogi	Redasemtide	—	ACTIVE NOT RECRUITING	2026-06-30	NCT05953480
PT. Prodia Stem Cell Indonesia	Conditioned Medium	—	ACTIVE NOT RECRUITING	2026-03	NCT05008588
Anthos Therapeutics, Inc.	Abelacimab	—	ACTIVE NOT RECRUITING	2024-02-15	NCT04755283
StemCyte, Inc.	hUCB	—	NOT YET RECRUITING	2027-12	NCT06040476
Abrexa Pharmaceuticals, Inc.	J147 Emulsion for Injection	—	NOT YET RECRUITING	2028-03-01	NCT07430917
Neurodawn Pharmaceutical Co., Ltd.	RK-4 injection	—	NOT YET RECRUITING	2026-02-20	NCT07166380
Organ, Tissue, Regeneration, Repair and Replacement	—	—	COMPLETED	2025-11-18	NCT06700824
Silver Creek Pharmaceuticals	scp776 (1.9 mg/kg)	—	COMPLETED	2025-09-15	NCT05585606
Moleac Pte Ltd.	MLC1501	—	COMPLETED	2025-07-18	NCT05289947
Lumosa Therapeutics Co., Ltd.	LT3001 Drug Product	—	COMPLETED	2025-05-23	NCT05403866
Shanghai Hutchison Pharmaceuticals Limited	3 ampoules of SHPL-49 Injection	—	COMPLETED	2024-11-26	NCT06202378
AbbVie	Elezanumab	—	COMPLETED	2024-04-18	NCT04309474
aptaTargets S.L.	ApTOLL	—	COMPLETED	2022-07-25	NCT04734548
Bristol-Myers Squibb	BMS-986177	—	COMPLETED	2022-03-31	NCT03766581
Bayer	BAY2433334	—	COMPLETED	2022-02-18	NCT04304508
Clinuvel Pharmaceuticals Limited	Afamelanotide	—	COMPLETED	2022-02-04	NCT04962503
Acticor Biotech	Intravenous ACT017 1000 mg	—	COMPLETED	2021-09-27	NCT03803007
Lumosa Therapeutics Co., Ltd.	LT3001 Drug Product	—	COMPLETED	2021-02-22	NCT04091945
Teijin Pharma Limited	JTR-161	—	COMPLETED	2021-02-15	NCT04608838
Shin Poong Pharmaceutical Co. Ltd.	SP-8203	—	COMPLETED	2020-10-19	NCT04479449
DiaMedica Therapeutics Inc	Recombinant human tissue kallikrein	—	COMPLETED	2020-01-23	NCT03290560
Daiichi Sankyo	DS-1040b	—	COMPLETED	2019-08-13	NCT02586233
SanBio, Inc.	SB623 Implant (2.5M)	—	COMPLETED	2018-12-05	NCT02448641
AdvanceCor GmbH	Revacept	—	COMPLETED	2018-10-05	NCT01645306
Biogen	natalizumab	Integrin Receptor Antagonist [EPC]	COMPLETED	2017-11-20	NCT02730455
Stemedica Cell Technologies, Inc.	Allogeneic adult mesenchymal bone marrow stem cells	—	COMPLETED	2017-09	NCT01297413
Shin Poong Pharmaceutical Co. Ltd.	SP-8203 High dose	—	COMPLETED	2017-05-30	NCT02787278
ZZ Biotech, LLC	3K3A-APC	—	COMPLETED	2017-04-18	NCT02222714
Genervon Biopharmaceuticals, LLC	GM602	—	COMPLETED	2016-07-07	NCT01221246
Remedy Pharmaceuticals, Inc.	Glyburide for Injection	—	COMPLETED	2016-04-04	NCT01794182
SanBio, Inc.	SB623	—	COMPLETED	2015-08	NCT01287936
Healios K.K.	MultiStem	—	COMPLETED	2015-03	NCT01436487
Biogen	natalizumab	Integrin Receptor Antagonist [EPC]	COMPLETED	2015-02	NCT01955707
Jiangsu Simcere Pharmaceutical Co., Ltd.	Compound Edaravone Injection	—	COMPLETED	2014-12	NCT01929096
Grifols Therapeutics LLC	Plasmin (Human)	—	COMPLETED	2013-11	NCT01014975
Lundbeck Japan K. K.	Desmoteplase	—	COMPLETED	2013-08	NCT01104467
Acorda Therapeutics	placebo/dalfampridine-ER	—	COMPLETED	2013-02	NCT01605825
Remedy Pharmaceuticals, Inc.	Glyburide for Injection	—	COMPLETED	2012-06-07	NCT01268683
Sygnis Bioscience GmbH & Co KG	Filgrastim	Leukocyte Growth Factor [EPC]	COMPLETED	2011-11	NCT00927836
NoNO Inc.	NA-1	—	COMPLETED	2011-04	NCT00728182
MindFrame, Inc.	—	—	COMPLETED	2011-04	NCT00810095
Tanabe Pharma Corporation	MCI-186	—	COMPLETED	2010-11	NCT00821821
Obslap Research LLC	—	—	COMPLETED	2010-09	NCT00919906
M's Science Corporation	SA4503 Low	—	COMPLETED	2009-06	NCT00639249
Orion Corporation, Orion Pharma	Levosimendan	—	COMPLETED	2009-04	NCT00698763
Moleac Pte Ltd.	Neuroaid	—	COMPLETED	2008-07	NCT00721825
ReNeuron Limited	Placebo	—	TERMINATED	2020-09-09	NCT03629275
Tanabe Pharma Corporation	Continuous infusion high-dose MCI-186	—	TERMINATED	2018-05-14	NCT03346538
Dart NeuroScience, LLC	DNS-3379	—	TERMINATED	2017-12-31	NCT03254160
Dart NeuroScience, LLC	HT-3951	—	TERMINATED	2017-12-31	NCT02530307
Roche	Basmisanil	—	TERMINATED	2017-11-03	NCT02928393
GSK	GSK249320 100/mg	—	TERMINATED	2014-07-28	NCT01808261
Pfizer	PF-03049423	—	TERMINATED	2013-12	NCT01208233
Stem Cell Therapeutics Corp.	human chorionic gonadotropin (hCG), then epoetin alfa (EPO)	—	TERMINATED	2010-04	NCT00938314
Stem Cell Therapeutics Corp.	NTx™-265: rhCG, then rEPO	—	TERMINATED	2008-10	NCT00663416
Nanjing Yoko Biomedical Co., Ltd.	Compound Edaravone Injection-Low dose	—	SUSPENDED	2026-12-31	NCT04984577
Biogen	BIIB131	—	WITHDRAWN	2025-07-07	NCT05764122
AZTherapies, Inc.	Cromolyn	—	WITHDRAWN	2024-12	NCT03202147
Techfields Inc	TF0023	—	SUSPENDED	2024-10	NCT02785120
TrueBinding, Inc.	TB006	—	WITHDRAWN	2023-12-18	NCT05156827
OsciFlex LLC	—	—	WITHDRAWN	2022-12	NCT05389488
Roche	Balovaptan	—	WITHDRAWN	2022-11-17	NCT05399550
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Pinocembrin for Injection	—	SUSPENDED	2016-12	NCT02059785
Daiichi Sankyo	SUN13837	—	WITHDRAWN	2016-05	NCT02258880
Ageless Regenerative Institute	—	—	WITHDRAWN	2014-12	NCT01453829
Stempeutics Research Pvt Ltd	Ex vivo cultured adult allogenic MSCs	—	WITHDRAWN	2013-05	NCT01091701
Stem Cell Therapeutics Corp.	NTx™-265: rhCG, then rEPO	—	WITHDRAWN	2010-06	NCT00715364

Showing 42 of 42 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Longwood Pharmaceuticals (Hangzhou) Co., Ltd.	LWP779	—	RECRUITING	2026-07-10	NCT07371455
Chendu DIAO Nine Hong Pharmaceutical Factory	DA414 Granules	—	RECRUITING	2025-09-30	NCT06525168
Algernon Pharmaceuticals	N,N-Dimethyltryptamine	—	ACTIVE NOT RECRUITING	2026-03	NCT05559931
BOE Technology Group Co., Ltd.	Human Umbilical Cord Mesenchymal Stem Cells Injection	—	NOT YET RECRUITING	2028-03-30	NCT07628933
S&Ebio Co. Ltd.	SNE-101	—	NOT YET RECRUITING	2026-03-31	NCT06995625
Jiangsu Kanion Pharmaceutical Co., Ltd	Single dose, AAPB by injection, intravenous drip.	—	NOT YET RECRUITING	2026-01-12	NCT06679998
Beijing Suncadia Pharmaceuticals Co., Ltd	HRS-4029	—	NOT YET RECRUITING	2025-10	NCT06905314
R3 Stem Cell	Amniotic and Umbilical Cord Tissue Procedure	—	NOT YET RECRUITING	2024-03-20	NCT03899298
Allife Medical Science and Technology Co., Ltd.	iEPCs	—	COMPLETED	2025-04-15	NCT05993884
Fujian Shengdi Pharmaceutical Co., Ltd.	HRS-7450	—	COMPLETED	2025-03-18	NCT06447415
Prolong Pharmaceuticals	PP-007 (Two doses administered 24±6 hours apart) + SOC (IVT or MT or IVT+MT)	—	COMPLETED	2025-02-20	NCT04677777
Motric Bio	MTR-601	—	COMPLETED	2024-10-16	NCT06117020
Changzhou Qianhong Bio-pharma Co., Ltd.	QHRD106 Injection	—	COMPLETED	2023-11-16	NCT06380699
NoNO Inc.	NoNO-42	—	COMPLETED	2023-10-05	NCT05636306
Bayer	Asundexian (BAY2433334)	—	COMPLETED	2023-05-24	NCT05419635
Jiangsu Simcere Pharmaceutical Co., Ltd.	SIM1910-09	—	COMPLETED	2023-03-23	NCT05200728
Dr. Noah Biotech Inc.	NDC-002	—	COMPLETED	2023-03-15	NCT06090474
Changzhou Qianhong Bio-pharma Co., Ltd.	QHRD106 Injection	—	COMPLETED	2022-07-22	NCT06388772
aptaTargets S.L.	ApTOLL	—	COMPLETED	2022-06-24	NCT05569720
Lumosa Therapeutics Co., Ltd.	LT3001 drug product	—	COMPLETED	2021-08-05	NCT04809818
Moleac Pte Ltd.	MLC1501	—	COMPLETED	2020-05-16	NCT04233437
aptaTargets S.L.	ApTOLL	—	COMPLETED	2020-02-27	NCT04742062
Shin Poong Pharmaceutical Co. Ltd.	SP-8008 Prototype Capsule A	—	COMPLETED	2020-01-23	NCT04770194
Aeromics, Inc.	AER-271	—	COMPLETED	2019-07-18	NCT03804476
Gwo Xi Stem Cell Applied Technology Co., Ltd.	ADSCs	—	COMPLETED	2018-11-27	NCT02813512
NuvOx LLC	0.05 mL/kg DDFPe	—	COMPLETED	2018-07-09	NCT02963376
DiaMedica Therapeutics Inc	Recombinant human tissue kallikrein	—	COMPLETED	2017-03	NCT02868996
Bristol-Myers Squibb	BMS-986141	—	COMPLETED	2016-11	NCT02922452
Jeil Pharmaceutical Co., Ltd.	JPI-289	—	COMPLETED	2015-08	NCT02396069
Shin Poong Pharmaceutical Co. Ltd.	SP-8203	—	COMPLETED	2015-03-11	NCT01757795
Jeil Pharmaceutical Co., Ltd.	JPI-289	—	COMPLETED	2014-08	NCT01983358
Daiichi Sankyo	DS-1040b	—	COMPLETED	2014-02	NCT02071004
Rapid Medical	—	—	COMPLETED	2013-10	NCT01404403
Posit Science Corporation	—	—	COMPLETED	2013-07	NCT01641432
ReNeuron Limited	CTX0E03 neural stem cells	—	COMPLETED	2012-10	NCT01151124
H. Lundbeck A/S	Lu AA24493 (CEPO)	—	COMPLETED	2010-12	NCT00870844
Biogen	Glyburide for Injection	—	COMPLETED	2010-05-07	NCT01132703
Wyeth is now a wholly owned subsidiary of Pfizer	ILS-920	—	COMPLETED	2009-07	NCT00827190
Johnson & Johnson	CNTO 0007 or placebo (Stage A)	—	COMPLETED	—	NCT01273467
Shin Poong Pharmaceutical Co. Ltd.	SP-8356	—	TERMINATED	2021-10-28	NCT05574166
Pulse Therapeutics	—	—	TERMINATED	2014-01	NCT01519076
Suzhou Yabao Pharmaceutical R&D Co., Ltd.	SY-007/ Placebo 15mg	—	SUSPENDED	2023-12-25	NCT04891913

Novel Stroke Drugs by Company (New molecular entities)

3 companies have an FDA-approved novel drug for Stroke.

SHINE 1 drug

NEUROLITE

TECHNETIUM TC-99M BICISATE KIT

NDA 1994

DAIICHI SANKYO INC 1 drug

GE HEALTHCARE 1 drug

TECHNETIUM TC-99M EXAMETAZIME KIT

NDA 1988

Reformulations (23 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.